Obesity and diabetes agents

Comprehensive database of GLP-1 and related clinical trial outcomes

Trial results

31917

Study

AllACCESS (phase 2b, aleniglipron)ACCESS II (higher-dose extension cohort, topline)ACHIEVE-1ACHIEVE-2ACHIEVE-3ACHIEVE-4ACHIEVE-JALPINE 2/3ALPINE-4Ambery et alAMPLITUDE-MAMPLITUDE-OAMPLITUDE-O ExploratoryAMYCRETINARCONARGON-1Aroda VR et alAROINHBE-1001ATLASATTAIN-1ATTAIN-2ATTAIN-MAINTAINBALANCEBALANCED Phase 2aBARI-STEPBELIEVEBillings KL et alBlüher et alBofanglutide phase 2b (Ji 2026)Bofanglutide vs semaglutide phase 2b T2D (Liu 2026)Browne et alCENTAURCOMBINE 4Coskun et alCT388-103 trialDA-302168S phase 1 (Zheng 2025)Dapiglutide phase 2a proof-of-concept (Nielsen 2026)DREAMS-1DREAMS-2DREAMS-3 Phase 3DUET Phase 2aEECOH-1 (ecnoglutide phase 3 T2D)EECOH-2Efimosfermin alfa (BOS-580) trialEfsubaglutide alfa biweekly-dosing randomised trial (Sun 2026)EMBRAZEEMMINENCE Phase 2bENLIVEN Phase 2bENTRIGUE (pegozafermin)ENTRIGUE-MIRNAESSENCEFASCINATE Phase 2bFLIGHT-FXRFlint A et alFLOWFLOW SGLT2Frias et alFrias JP et alGLORY-1GLORY-2Gómez-Romero M et alGZR18 phase 1b/2a (Ji 2026)GZR18 phase 1b/2a T2D (Liu 2026)HARMONYHarrison S et alHarrison SA et alHDM1002 phase 1b (Xu 2026)Heise T et alHR17031 phase 2 (Ji 2025)HRS-7535 phase 2 (Gu 2026)IMPACTIMPACT Phase 2bION224-CS2IONIS-DGAT2Ixekizumab with or without tirzepatide phase 3b (Lebwohl 2026)Jastreboff et alJi L et al (ecnoglutide, 2025)Ji L et al (mazdutide, 2023)KN069 phase 1 (Xie 2026)Lacobellis G et alLau et alLe Roux CW et alLi W et alLoomba R et al (efimosfermin alfa, 2025)Loomba R et al (pegozafermin, 2023)LY2963016 insulin glargine (Basaglar)MAESTRO-NASHMariTide Phase 2 ObesityMather KJ et alMazdutide (IB1362)Mazdutide phase 1 (Bhattachar 2025)Mazdutide US phase 2 (Hsia 2026)MIRNAMOMENTUMNahra R et alNATIVENative GIP infusion randomised trial (Helsted 2026)Newsome P.N et alNN9931-4296NN9931-4492 InvestigatorsOASIS 1OASIS 2OASIS 4Orforglipron phase 1 (Ohwaki 2026)OUTSTAND-1Parker V.E.R et alPatel K et alPetrelintide phase 1PG-102 phase 1 (Yang 2026)PIONEER 1PIONEER 10PIONEER 11PIONEER 12PIONEER 2PIONEER 3PIONEER 4PIONEER 5PIONEER 6PIONEER 7PIONEER 8PIONEER 9PIONEER PLUSPROXYMOREDEFINE 1REDEFINE 2REDEFINE 4REDEFINE 5REGENERATEREIMAGINE 2REIMAGINE 3REMODELRosenstock et alSAMARASanyal A et alSanyal et alSELECTSELECT CKDSELECT MWSELECT SubstudySelvarajah et alSEMA-VR CardioLink-15SEPRAShah VN et alSiddiqui MS et alSMARTSOLSTICESOULSTEP 1STEP 1 ExtendedSTEP 10STEP 11STEP 12STEP 2STEP 3STEP 4STEP 5STEP 6STEP 7STEP 8STEP 9STEP HFpEFSTEP HFpEF DMSTEP TEENSSTEP UPSTEP UP MRI substudy (Hjelmesaeth 2026)STEP UP T2DSTRIDESUMMIT-1SUMMIT-CMR SubstudySUPER1SURMOUNT-1SURMOUNT-1 (Study 2)SURMOUNT-2SURMOUNT-3SURMOUNT-4SURMOUNT-5SURMOUNT-CNSURMOUNT-MAINTAINSURMOUNT-OSASURMOUNT-OSA (Trial 1)SURMOUNT-OSA (Trial 2)SURPASS J-monoSURPASS-1SURPASS-2SURPASS-3SURPASS-3 MRISURPASS-4SURPASS-5SURPASS-6SURPASS-CN-INSSURPASS-CVOTSURPASS-EARLYSURPASS-PEDSSUSTAIN 1SUSTAIN 10SUSTAIN 11SUSTAIN 2SUSTAIN 3SUSTAIN 4SUSTAIN 5SUSTAIN 6SUSTAIN 7SUSTAIN 8SUSTAIN 9SUSTAIN FORTESYMMETRYSYNCHRONIZE-1SYNCHRONIZE-2SYNCHRONIZE-MASLDSYNERGY-NASHTIRTLE1TRANSCEND-T2D-1TRIUMPH-1TRIUMPH-2TRIUMPH-4VENTURE (subcutaneous VK2735)VENTURE OralVESPER-1VISTAVOYAGEWharton et alZalfermin plus semaglutide MASH phase 2 (Loomba 2026)Zenagamtide oral phase 2 (Mora 2026)Zenagamtide subcutaneous phase 2 (Mora 2026)Zhang B et alZhao L et alZhou J et alZhu D et alZUPREME-1

Drug

AllAldaferminAleniglipronAll armsAlternative treatmentApitegromabAramcholARO-INHBEBimagrumabBimagrumab + semaglutideBofanglutideCagrilintideCagriSemaCanagliflozinCenicrivirocCilofexorCilofexor/FirsocostatCilofexor/SelonsertibCotadutideCT388-103DA-302168SDapagliflozinDapiglutideDenifanstatDulaglutideEcnoglutideEDP-305EfimosferminEfinopegdutideEfpeglenatideEfruxiferminEfsubaglutide alfaElecoglipronEloralintideEmpagliflozinErvogastatExenatideFirsocostatFirsocostat/SelonsertibGIPHDM1002HR17031HRS-7535HRS9531IcoSemaINS068InsulinInsulin degludecInsulin glargineIntensified conventional careION224IONIS-DGAT2RxIxekizumabIxekizumab plus tirzepatideKN069LanifibranorLiraglutideLY2963016 insulin glargineMariTideMazdutideMEDI0382MEDI0383MEDI0384MEDI0385MEDI0386MEDI0388MEDI0389MEDI0390MEDI0391MEDI0392MEDI0393MEDI0394MEDI0395MET-097iMSDC-0602KNoiiglutideObeticholic acidOrforglipronPegozaferminPemvidutidePetrelintidePG-102PlaceboPlacebo then aleniglipronPlacebo then ecnoglutidePlacebo then mazdutideResmetiromRetatrutideSafiglipronSaroglitazarSemaglutideSemaglutide + GIPSGLT-2 inhibitorsSitagliptinSurvodutideTERN-101TERN-501TirzepatideTropifexorUsual careVK2735VK2809ZalferminZalfermin + semaglutideZenagamtide

Mechanism

AllACC inhibitorActivin/myostatin pathway inhibitorAmylin receptor agonistASK1 inhibitorBasal insulin analogCalcitonin receptor agonistCCR2/CCR5 antagonistDGAT2 inhibitorDPP-4 inhibitorFASN inhibitorFGF19 analogFGF21 analogFXR agonistGIP receptor agonistGIP receptor antagonistGLP-1 receptor agonistGLP-2 receptor agonistGlucagon receptor agonistIL-17 inhibitorMitochondrial pyruvate carrier modulator (insulin sensitizer)PPAR agonistSCD1 inhibitorSGLT2 inhibitorTHR-beta agonist

Match

Outcome

Weight change (%)

Phase

Diabetes Status

Administration

Show placebo effect

Pool estimates

Select studies to pool using fixed‑effect IV weighting.

Aleniglipron 180 mgACCESS II (higher-dose extension cohort, topline)

Aleniglipron 240 mgACCESS II (higher-dose extension cohort, topline)

Aleniglipron 120 mgACCESS (phase 2b, aleniglipron)

Aleniglipron 45 mgACCESS (phase 2b, aleniglipron)

Aleniglipron 90 mgACCESS (phase 2b, aleniglipron)

Orforglipron 12 mgACHIEVE-1

Orforglipron 36 mgACHIEVE-1

Orforglipron 3 mgACHIEVE-1

Dapagliflozin 10 mgACHIEVE-2

Orforglipron 12 mgACHIEVE-2

Orforglipron 36 mgACHIEVE-2

Orforglipron 3 mgACHIEVE-2

Orforglipron 12 mgACHIEVE-3

Orforglipron 36 mgACHIEVE-3

Semaglutide 14 mgACHIEVE-3

Semaglutide 7 mgACHIEVE-3

Insulin glargineACHIEVE-4

Orforglipron 36 mgACHIEVE-4

Orforglipron 12 mgACHIEVE-J

Orforglipron 36 mgACHIEVE-J

Orforglipron 3 mgACHIEVE-J

Zenagamtide 1.25 mgAMYCRETIN

Zenagamtide 20 mgAMYCRETIN

Zenagamtide 5 mgAMYCRETIN

Zenagamtide 60 mgAMYCRETIN

Semaglutide 16 mgAroda VR et al

Semaglutide 2 mgAroda VR et al

Semaglutide 8 mgAroda VR et al

ARO-INHBE 400 mg + TirzepatideAROINHBE-1001

TirzepatideAROINHBE-1001

Orforglipron 12 mgATTAIN-1

Orforglipron 36 mgATTAIN-1

Orforglipron 6 mgATTAIN-1

Orforglipron 12 mgATTAIN-2

Orforglipron 36 mgATTAIN-2

Orforglipron 6 mgATTAIN-2

Orforglipron 36 mgATTAIN-MAINTAIN

Efpeglenatide 4 mgBALANCE

Efpeglenatide 6 mgBALANCE

Efpeglenatide 8 mgBALANCE

Semaglutide 2.4 mgBARI-STEP

Bimagrumab 10→30 mg/kgBELIEVE

Bimagrumab 10 mg/kgBELIEVE

Bimagrumab 10 mg/kg + Semaglutide 1.0 mgBELIEVE

Bimagrumab 10 mg/kg + Semaglutide 2.4 mgBELIEVE

Bimagrumab 30 mg/kgBELIEVE

Bimagrumab 30 mg/kg + Semaglutide 1.0 mgBELIEVE

Bimagrumab 30 mg/kg + Semaglutide 2.4 mgBELIEVE

Semaglutide 1.0 mgBELIEVE

Semaglutide 2.4 mgBELIEVE

Eloralintide 1 mgBillings KL et al

Eloralintide 3–9 mgBillings KL et al

Eloralintide 3 mgBillings KL et al

Eloralintide 6–9 mgBillings KL et al

Eloralintide 6 mgBillings KL et al

Eloralintide 9 mgBillings KL et al

Semaglutide 1.0 mgBlüher et al

Survodutide 1.8 mgBlüher et al

Bofanglutide 12 mgBofanglutide phase 2b (Ji 2026)

Bofanglutide 18 mgBofanglutide phase 2b (Ji 2026)

Bofanglutide 24 mg (Q2W)Bofanglutide phase 2b (Ji 2026)

Bofanglutide 24 mg (QW)Bofanglutide phase 2b (Ji 2026)

Bofanglutide 48 mgBofanglutide phase 2b (Ji 2026)

Pemvidutide 1.2 mgBrowne et al

Pemvidutide 1.8 mgBrowne et al

Pemvidutide 2.4 mgBrowne et al

CT388-103 24 mgCT388-103 trial

DA-302168S 15 mgDA-302168S phase 1 (Zheng 2025)

DA-302168S 20 mg (high titration)DA-302168S phase 1 (Zheng 2025)

DA-302168S 20 mg (low titration)DA-302168S phase 1 (Zheng 2025)

DA-302168S 30 mgDA-302168S phase 1 (Zheng 2025)

DA-302168S 7.5 mgDA-302168S phase 1 (Zheng 2025)

Dapiglutide 4 mgDapiglutide phase 2a proof-of-concept (Nielsen 2026)

Dapiglutide 6 mgDapiglutide phase 2a proof-of-concept (Nielsen 2026)

Mazdutide 4 mgDREAMS-1

Mazdutide 6 mgDREAMS-1

Dulaglutide 1.5 mgDREAMS-2

Mazdutide 4 mgDREAMS-2

Mazdutide 6 mgDREAMS-2

Mazdutide 6 mgDREAMS-3 Phase 3

Semaglutide 1 mgDREAMS-3 Phase 3

Ecnoglutide 0.6 mgEECOH-1 (ecnoglutide phase 3 T2D)

Ecnoglutide 1.2 mgEECOH-1 (ecnoglutide phase 3 T2D)

Dulaglutide 1.5 mgEECOH-2

Ecnoglutide 0.6 mgEECOH-2

Ecnoglutide 1.2 mgEECOH-2

Pegozafermin 30 mg QWENLIVEN Phase 2b

Pegozafermin 44 mg Q2WENLIVEN Phase 2b

Semaglutide 2.4 mgESSENCE

Semaglutide 0.4 mgFlint A et al

Dulaglutide 1.5 mgFrias et al

Orforglipron 12 mgFrias et al

Orforglipron 24 mgFrias et al

Orforglipron 36 mgFrias et al

Orforglipron 3 mgFrias et al

Orforglipron 45 mgFrias et al

Cagrilintide 2.4 mgFrias JP et al

Cagrilintide Semaglutide 2.4 mgFrias JP et al

Semaglutide 2.4 mgFrias JP et al

Mazdutide 4 mgGLORY-1

Mazdutide 6 mgGLORY-1

Mazdutide 9 mgGLORY-2

Efinopegdutide 10 mgGómez-Romero M et al

Semaglutide 1 mgGómez-Romero M et al

Bofanglutide 30 mg Q2W (Part B)GZR18 phase 1b/2a (Ji 2026)

Bofanglutide 30 mg QW (Part B)GZR18 phase 1b/2a (Ji 2026)

Bofanglutide 4.8 mg QW (Part A)GZR18 phase 1b/2a (Ji 2026)

Bofanglutide 13 mgGZR18 phase 1b/2a T2D (Liu 2026)

Bofanglutide 4 mgGZR18 phase 1b/2a T2D (Liu 2026)

Efruxifermin 50 mgHarrison SA et al

Pemvidutide 1.2 mgHarrison S et al

Pemvidutide 1.8 mgHarrison S et al

Pemvidutide 2.4 mgHarrison S et al

HDM1002 200 mg QDHDM1002 phase 1b (Xu 2026)

HDM1002 400 mg QDHDM1002 phase 1b (Xu 2026)

HRS-7535 120 mgHRS-7535 phase 2 (Gu 2026)

HRS-7535 180 mgHRS-7535 phase 2 (Gu 2026)

HRS-7535 30 mgHRS-7535 phase 2 (Gu 2026)

HRS-7535 60 mgHRS-7535 phase 2 (Gu 2026)

Pemvidutide 1.2 mgIMPACT Phase 2b

Pemvidutide 1.8 mgIMPACT Phase 2b

Active comparatorIxekizumab with or without tirzepatide phase 3b (Lebwohl 2026)

ExperimentalIxekizumab with or without tirzepatide phase 3b (Lebwohl 2026)

Retatrutide 12 mg (ID2)Jastreboff et al

Retatrutide 1 mgJastreboff et al

Retatrutide 4 mg (ID2)Jastreboff et al

Retatrutide 4 mg (ID4)Jastreboff et al

Retatrutide 8 mg (ID2)Jastreboff et al

Retatrutide 8 mg (ID4)Jastreboff et al

Ecnoglutide 1.2 mgJi L et al (ecnoglutide, 2025)

Ecnoglutide 1.8 mgJi L et al (ecnoglutide, 2025)

Ecnoglutide 2.4 mgJi L et al (ecnoglutide, 2025)

Mazdutide 3 mgJi L et al (mazdutide, 2023)

Mazdutide 4.5 mgJi L et al (mazdutide, 2023)

Mazdutide 6 mgJi L et al (mazdutide, 2023)

KN069 12 mg (SAD)KN069 phase 1 (Xie 2026)

KN069 15/30/30 mg (MAD Group A)KN069 phase 1 (Xie 2026)

KN069 15/30/60 mg (MAD Group B)KN069 phase 1 (Xie 2026)

KN069 30 mg (SAD)KN069 phase 1 (Xie 2026)

KN069 60 mg (SAD)KN069 phase 1 (Xie 2026)

KN069 90 mg (SAD)KN069 phase 1 (Xie 2026)

Cagrilintide 0.3 mgLau et al

Cagrilintide 0.6 mgLau et al

Cagrilintide 1.2 mgLau et al

Cagrilintide 2.4 mgLau et al

Cagrilintide 4.5 mgLau et al

Liraglutide 3.0 mgLau et al

Survodutide 0.6 mgLe Roux CW et al

Survodutide 2.4 mgLe Roux CW et al

Survodutide 3.6 mgLe Roux CW et al

Survodutide 4.8 mgLe Roux CW et al

Pegozafermin 15 mg QWLoomba R et al (pegozafermin, 2023)

Pegozafermin 30 mg QWLoomba R et al (pegozafermin, 2023)

Pegozafermin 44 mg Q2WLoomba R et al (pegozafermin, 2023)

280 mgMariTide Phase 2 Obesity

MariTide 140 mg Q4W (no DE)MariTide Phase 2 Obesity

MariTide 280 mg Q4W (no DE)MariTide Phase 2 Obesity

MariTide 420 mg Q4W (12-wk DE)MariTide Phase 2 Obesity

MariTide 420 mg Q4W (4-wk DE)MariTide Phase 2 Obesity

MariTide 420 mg Q4W (no DE)MariTide Phase 2 Obesity

MariTide 420 mg Q8W (no DE)MariTide Phase 2 Obesity

Mazdutide 10 mgMazdutide (IB1362)

Mazdutide 9 mgMazdutide (IB1362)

Mazdutide 16 mg (Cohort 1)Mazdutide phase 1 (Bhattachar 2025)

Mazdutide 16 mg (Cohort 2)Mazdutide phase 1 (Bhattachar 2025)

Mazdutide 10 mgMazdutide US phase 2 (Hsia 2026)

Mazdutide 16 mgMazdutide US phase 2 (Hsia 2026)

Mazdutide 3–6 mgMazdutide US phase 2 (Hsia 2026)

Pemvidutide 1.2 mgMOMENTUM

Pemvidutide 1.8 mgMOMENTUM

Pemvidutide 2.4 mgMOMENTUM

Cotadutide 100 µgNahra R et al

Cotadutide 200 µgNahra R et al

Cotadutide 300 µgNahra R et al

Liraglutide 1.8 mgNahra R et al

Semaglutide 0.1 mgNewsome P.N et al

Semaglutide 0.2 mgNewsome P.N et al

Semaglutide 0.4 mgNewsome P.N et al

Semaglutide 0.4 mgNN9931-4296

Semaglutide 2.4 mgNN9931-4492 Investigators

Semaglutide 50 mgOASIS 1

Semaglutide 50 mgOASIS 2

Semaglutide 25 mgOASIS 4

Safiglipron 30 mgOUTSTAND-1

Safiglipron 60 mgOUTSTAND-1

Safiglipron 90 mgOUTSTAND-1

Cotadutide (50→300 µg)Parker V.E.R et al

Cilofexor 100 mgPatel K et al

Cilofexor 30 mgPatel K et al

Petrelintide 2.4 mgPetrelintide phase 1

Petrelintide 4.8 mgPetrelintide phase 1

Petrelintide 9.0 mgPetrelintide phase 1

PG-102 15 mgPG-102 phase 1 (Yang 2026)

PG-102 30/60 mgPG-102 phase 1 (Yang 2026)

PG-102 30 mgPG-102 phase 1 (Yang 2026)

Dulaglutide 0,75 mgPIONEER 10

Semaglutide 14 mgPIONEER 10

Semaglutide 3 mgPIONEER 10

Semaglutide 7 mgPIONEER 10

Semaglutide 14 mgPIONEER 11

Semaglutide 3 mgPIONEER 11

Semaglutide 7 mgPIONEER 11

Semaglutide 14 mgPIONEER 3

Semaglutide 3 mgPIONEER 3

Semaglutide 7 mgPIONEER 3

SitagliptinPIONEER 3

Liraglutide 1.8 mgPIONEER 4

Semaglutide 14 mgPIONEER 4

Semaglutide 14 mgPIONEER 7

SitagliptinPIONEER 7

Semaglutide 14 mgPIONEER PLUS

Semaglutide 25 mgPIONEER PLUS

Semaglutide 50 mgPIONEER PLUS

Cagrilintide 2.4 mgREDEFINE 1

Cagrilintide Semaglutide 2.4+2.4 mgREDEFINE 1

Semaglutide 2.4 mgREDEFINE 1

Cagrilintide Semaglutide 2.4+2.4 mgREDEFINE 2

Cagrilintide Semaglutide 2.4 mgREDEFINE 4

Tirzepatide 15 mgREDEFINE 4

Cagrilintide Semaglutide 2.4+2.4 mgREDEFINE 5

Semaglutide 2.4 mgREDEFINE 5

Cagrilintide 2.4 mgREIMAGINE 2

CagriSema 1.0 mg/1.0 mgREIMAGINE 2

CagriSema 2.4 mg/2.4 mgREIMAGINE 2

Semaglutide 1.0 mgREIMAGINE 2

Semaglutide 2.4 mgREIMAGINE 2

CagriSema 1.0 mg/1.0 mgREIMAGINE 3

CagriSema 2.4 mg/2.4 mgREIMAGINE 3

Dulaglutide 1.5 mgRosenstock et al

Retatrutide 0.5 mgRosenstock et al

Retatrutide 12 mg (starting 2 mg)Rosenstock et al

Retatrutide 4 mg (no escalation)Rosenstock et al

Retatrutide 4 mg (starting 2 mg)Rosenstock et al

Retatrutide 8 mg (starting 2 mg)Rosenstock et al

Retatrutide 8 mg (starting 4 mg)Rosenstock et al

Semaglutide 2.4 mgSAMARA

Survodutide 2.4 mgSanyal A et al

Survodutide 4.8 mgSanyal A et al

Survodutide 6.0 mgSanyal A et al

Retatrutide 12 mgSanyal et al

Retatrutide 1 mgSanyal et al

Retatrutide 4 mgSanyal et al

Retatrutide 8 mgSanyal et al

Semaglutide 2.4 mgSELECT Substudy

Cotadutide 100 μgSelvarajah et al

Cotadutide 300 μgSelvarajah et al

Cotadutide 600 μgSelvarajah et al

Semaglutide 1 mgSelvarajah et al

Alternative treatmentSEPRA

SemaglutideSEPRA

Elecoglipron 15 mgSOLSTICE

Elecoglipron 25 mgSOLSTICE

Elecoglipron 50 mg (every 2-week dose escalation)SOLSTICE

Elecoglipron 5 mgSOLSTICE

Elecoglipron 75 mg (every 2-week dose escalation)SOLSTICE

Elecoglipron 75 mg (every 4-week dose escalation)SOLSTICE

Elecoglipron 75 mg (pooled)SOLSTICE

Semaglutide 14 mgSOLSTICE

Semaglutide 2.4 mgSTEP 1

Semaglutide 2.4 mgSTEP 10

Semaglutide 2.4 mgSTEP 11

Semaglutide 2.4 mgSTEP 12

Semaglutide 2.4 mgSTEP 1 Extended

Semaglutide 1.0 mgSTEP 2

Semaglutide 2.4 mgSTEP 2

Semaglutide 2.4 mgSTEP 3

Semaglutide 2.4 mgSTEP 4

Semaglutide 2.4 mgSTEP 5

Semaglutide 1.7 mgSTEP 6

Semaglutide 2.4 mgSTEP 6

Semaglutide 2.4 mgSTEP 7

Liraglutide 3.0 mgSTEP 8

Semaglutide 2.4 mgSTEP 8

Semaglutide 2.4 mgSTEP 9

Semaglutide 2.4 mgSTEP HFpEF

Semaglutide 2.4 mgSTEP HFpEF DM

Semaglutide 2.4 mgSTEP TEENS

Semaglutide 2.4 mgSTEP UP

Semaglutide 7.2 mgSTEP UP

Semaglutide (pooled doses)STEP UP MRI substudy (Hjelmesaeth 2026)

Semaglutide 2.4 mgSTEP UP T2D

Semaglutide 7.2 mgSTEP UP T2D

Tirzepatide 15 mgSUMMIT-1

Efsubaglutide alfa 1 mgSUPER1

Efsubaglutide alfa 3 mgSUPER1

Tirzepatide 10 mgSURMOUNT-1

Tirzepatide 15 mgSURMOUNT-1

Tirzepatide 5 mgSURMOUNT-1

Tirzepatide 10 mgSURMOUNT-1 (Study 2)

Tirzepatide 15 mgSURMOUNT-1 (Study 2)

Tirzepatide 5 mgSURMOUNT-1 (Study 2)

Tirzepatide 10 mgSURMOUNT-2

Tirzepatide 15 mgSURMOUNT-2

Tirzepatide MTDSURMOUNT-3

Tirzepatide MTDSURMOUNT-4

Semaglutide (MTD 1.7/2.4 mg)SURMOUNT-5

Tirzepatide (MTD 10/15 mg)SURMOUNT-5

Tirzepatide 10 mgSURMOUNT-CN

Tirzepatide 15 mgSURMOUNT-CN

Tirzepatide 5 mgSURMOUNT-MAINTAIN

Tirzepatide MTD (10 mg or 15 mg)SURMOUNT-MAINTAIN

Tirzepatide (10 mg or 15 mg) in Trial 1SURMOUNT-OSA (Trial 1)

Tirzepatide (10 mg or 15 mg) in Trial 2SURMOUNT-OSA (Trial 2)

Insulin degludecSURPASS-3 MRI

Tirzepatide 10 mgSURPASS-3 MRI

Tirzepatide 15 mgSURPASS-3 MRI

Tirzepatide 5 mgSURPASS-3 MRI

Tirzepatide (pooled doses)SURPASS-3 MRI

Insulin glargine 0.4 U/kg titratedSURPASS-4

Tirzepatide 10 mgSURPASS-4

Tirzepatide 15 mgSURPASS-4

Tirzepatide 5 mgSURPASS-4

DulaglutideSURPASS-CVOT

TirzepatideSURPASS-CVOT

Tirzepatide (pooled doses)SURPASS-CVOT

Intensified conventional careSURPASS-EARLY

Tirzepatide 15 mg or MTDSURPASS-EARLY

Insulin aspartSUSTAIN 11

Semaglutide 1.0 mgSUSTAIN 11

Survodutide 3.6 mgSYNCHRONIZE-1

Survodutide 6.0 mgSYNCHRONIZE-1

Survodutide 3.6 mgSYNCHRONIZE-2

Survodutide 6.0 mgSYNCHRONIZE-2

Survodutide 6.0 mgSYNCHRONIZE-MASLD

Tirzepatide 10 mgSYNERGY-NASH

Tirzepatide 15 mgSYNERGY-NASH

Tirzepatide 5 mgSYNERGY-NASH

Retatrutide 12 mgTRANSCEND-T2D-1

Retatrutide 4 mgTRANSCEND-T2D-1

Retatrutide 9 mgTRANSCEND-T2D-1

Retatrutide 12 mgTRIUMPH-1

Retatrutide 12 mg to maximum tolerated dose 9 or 12 mgTRIUMPH-1

Retatrutide 4 mgTRIUMPH-1

Retatrutide 4 mg to maximum tolerated dose 9 or 12 mgTRIUMPH-1

Retatrutide 9 mgTRIUMPH-1

Retatrutide 9 mg to maximum tolerated dose 9 or 12 mgTRIUMPH-1

Retatrutide 12 mgTRIUMPH-2

Retatrutide 4 mgTRIUMPH-2

Retatrutide 9 mgTRIUMPH-2

Retatrutide 12 mgTRIUMPH-4

Retatrutide 9 mgTRIUMPH-4

VK2735 120 mgVENTURE Oral

VK2735 15 mgVENTURE Oral

VK2735 30 mgVENTURE Oral

VK2735 60 mgVENTURE Oral

VK2735 90 mgVENTURE Oral

VK2735 10 mgVENTURE (subcutaneous VK2735)

VK2735 15 mgVENTURE (subcutaneous VK2735)

VK2735 2.5 mgVENTURE (subcutaneous VK2735)

VK2735 5 mgVENTURE (subcutaneous VK2735)

MET-097i 0.4 mgVESPER-1

MET-097i 0.6 mgVESPER-1

MET-097i 0.9 mgVESPER-1

MET-097i 1.2 mgVESPER-1

Orforglipron 12 mgWharton et al

Orforglipron 24 mgWharton et al

Orforglipron 36 mgWharton et al

Orforglipron 45 mgWharton et al

Cagrilintide 2·4 mg + semaglutide 2·4 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Semaglutide 2·4 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Zalfermin 15 mg + semaglutide 2·4 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Zalfermin 30 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Zalfermin 30 mg + semaglutide 2·4 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Zalfermin 7·5 mg + semaglutide 2·4 mgZalfermin plus semaglutide MASH phase 2 (Loomba 2026)

Zenagamtide 0.4 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

Zenagamtide 10 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

Zenagamtide 1.5 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

Zenagamtide 20 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

Zenagamtide 40 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

Zenagamtide 5 mg (subcutaneous)Zenagamtide subcutaneous phase 2 (Mora 2026)

HRS9531 1.0 mgZhao L et al

HRS9531 3.0 mgZhao L et al

HRS9531 4.5 mgZhao L et al

HRS9531 6.0 mgZhao L et al

Petrelintide 1.0 mgZUPREME-1

Petrelintide 2.5 mgZUPREME-1

Petrelintide 5.0 mgZUPREME-1

Petrelintide 7.0 mgZUPREME-1

Petrelintide 9.0 mgZUPREME-1

590 records

◆Diamond markers are subgroup results. Hover for details.